Finoriq research workspace
Arbutus Biopharma Corp (ABUS) SEC Filings & Filing Highlights
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel. Review ABUS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
- Company
- Arbutus Biopharma Corp (ABUS)
- Ticker
- ABUS
- Market Cap
- $878.1M
- Latest Price
- $4.445
- Industry
- Biotech & Pharma
Arbutus Biopharma Corp (ABUS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Arbutus Biopharma Corp (ABUS).
| Event | Form | Date |
|---|---|---|
| Arbutus Biopharma Corp: Shareholder voteOn May 26, 2026, the Company held the Annual Meeting. At the Annual Meeting, the Company’s shareholders voted and: (1) elected each of the... | 8-K5.07 | 2026-05-27 |
| 2026 Omnibus Share and Incentive Plan On May 26, 2026, Arbutus Biopharma Corporation (the “Comp...2026 Omnibus Share and Incentive Plan On May 26, 2026, Arbutus Biopharma Corporation (the “Company”) held its 2026 Annual General and Speci... | 8-K5.02 | 2026-05-27 |
| Arbutus Biopharma Corp: Earnings or resultsOn May 13, 2026, Arbutus Biopharma Corporation issued a press release announcing its financial results for the first quarter ended March 31... | 8-K2.02 | 2026-05-13 |
| Arbutus Biopharma Corp: Corporate updateOn April 15, 2026, Arbutus Biopharma Corporation issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has g... | 8-K8.01 | 2026-04-15 |
| Arbutus Biopharma Corp: Earnings or resultsOn March 23, 2026, Arbutus Biopharma Corporation issued a press release announcing its financial results for the fourth quarter and year en... | 8-K2.02 | 2026-03-23 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.